<DOC>
	<DOCNO>NCT02306954</DOCNO>
	<brief_summary>All patient receive IL-2 ( 14 plan dos additional cycle 14 day first ) . Responding patient regress disease eligible 6 IL-2 cycle . Patients assign SBRT arm receive two dos SBRT Wednesday Friday Monday IL-2 start .</brief_summary>
	<brief_title>Study High Dose Interleukin-2 ( IL-2 ) Stereotactic Body Radiation ( SBRT ) Patients With Metastatic Renal Cancer</brief_title>
	<detailed_description>All patient receive IL-2 600,000 international unit per kilogram ( kg ) intraveneous bolus ( IVB ) every 8 hour 14 planned dos additional cycle 14 day first . Responding patient regress disease eligible 6 IL-2 cycle . Patients assign SBRT arm receive two dos SBRT 20 Gray ( Gy ) Wednesday Friday Monday IL-2 start .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Histological confirmation predominant conventional ( clear cell ) renal cancer Patients must â‰¥ 18 year age Tumors amenable SBRT lung ( central location prefer ) , mediastinum , chest wall , bone soft tissue component ( long bone ) , liver , liver hilum associate lymph node ( inclusive immediately adjacent mass ) , 1 3 focus ; minimum size , none great 7 cm . Patients may metastases maximum 3 treated Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Women childbearing potential must negative serum urine pregnancy test within 72 hour prior start protocol treatment . In addition , woman childbearing potential well male patient must agree take appropriate precaution avoid pregnancy Patients must agree participate Prometheus IL2 patient registry ( PROCLAIM registry ) Patients must sign studyspecific consent form No metastatic site amenable SBRT Patients brain metastasis candidate radiosurgery alone Previous radiation site propose SBRT Patients active systemic , pulmonary , pericardial infection Pregnant lactate woman , treatment involve unforeseeable risk embryo fetus Evidence ischemia exercise tolerance test , stress thallium study , baseline EKG Clinically significant underlying pulmonary disease measure pulmonary function test Blood test within protocolspecified range Need chronic steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Kidney Cancer</keyword>
	<keyword>High Dose IL-2</keyword>
	<keyword>SBRT</keyword>
</DOC>